Healthy Living South Dakota: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living South Dakota.

September 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Press releases published on September 4, 2025

September 4, 2025

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

GlobeNewswire

September 4, 2025

Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports

GlobeNewswire

September 4, 2025

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire

September 4, 2025

Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

GlobeNewswire

September 4, 2025

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

GlobeNewswire

September 4, 2025

Breckenridge Distillery and Denver Broncos Kick Off Fifth Year of Partnership with New Lineup of Spirits, Including Limited-Edition Broncos Honey Whiskey

GlobeNewswire

September 4, 2025

Nusano Announces September Conference Schedule

GlobeNewswire

September 4, 2025

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

GlobeNewswire

September 4, 2025

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

GlobeNewswire

September 4, 2025

Walden Biosciences Announces Key Initiatives to Advance Clinical Pipeline and Support Phase 2 Program for WAL0921 in Rare Kidney Diseases

GlobeNewswire

September 4, 2025

Cancer Focus Fund Appoints Distinguished Industry Experts David R. Epstein and Michael Margolis as Advisors to Its Investment Committee

GlobeNewswire

September 4, 2025

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)

GlobeNewswire

September 4, 2025

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire

September 4, 2025

Algernon Pharmaceuticals Announces Name Change to Algernon Health

GlobeNewswire

September 4, 2025

Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

GlobeNewswire

September 4, 2025

Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10

GlobeNewswire

September 4, 2025

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

GlobeNewswire

September 4, 2025

GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire

September 4, 2025

Sol-Gel Announces Health Canada Approval of EPSOLAY®

GlobeNewswire

September 4, 2025

Merakris Therapeutics Enrolls 30th Subject in Expanded Access Program of MTX-001; Highlights Clinical Progress at SAWC Fall 2025

GlobeNewswire